Lars-Erik Rutqvist
Overview
Explore the profile of Lars-Erik Rutqvist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laytragoon Lewin N, Luetragoon T, Andersson B, Oliva D, Nilsson M, Strandeus M, et al.
Anticancer Res
. 2019 Mar;
39(3):1287-1292.
PMID: 30842160
Materials And Methods: Eighty-six female patients recovering from breast cancer surgery were investigated. As a control cohort, 82 healthy female blood donors were used. Blood-based SNPs, plasma C-reactive protein (CRP),...
2.
Andersson B, Lewin F, Lundgren J, Nilsson M, Rutqvist L, Lofgren S, et al.
J Cancer Res Clin Oncol
. 2014 Feb;
140(3):515-9.
PMID: 24481866
Purpose: Tumor TNM staging is the main basis for prognosis and treatment decision for head and neck squamous cell carcinoma (HNSCC) despite significant heterogeneity in terms of outcome among patients...
3.
Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial
Fahlen M, Fornander T, Johansson H, Johansson U, Rutqvist L, Wilking N, et al.
Eur J Cancer
. 2012 Aug;
49(1):52-9.
PMID: 22892060
Background: The management of hormonal deficiency symptoms in breast cancer survivors is an unsolved problem. While hormone replacement therapy (HRT) may increase the risk of breast cancer in healthy women,...
4.
Coggins C, Ballantyne M, Curvall M, Rutqvist L
Crit Rev Toxicol
. 2012 Mar;
42(4):304-13.
PMID: 22400986
Three commercial brands of Swedish snus (SWS), an experimental SWS, and the 2S3 reference moist snuff were each tested in four in vitro toxicology assays. These assays were: Salmonella reverse...
5.
Johnsson A, Fornander T, Rutqvist L, Olsson M
Work
. 2011 Apr;
38(4):337-46.
PMID: 21508523
Objective: The aims of this study were to generate new knowledge about factors predicting return to work (RTW) among women treated for early-stage breast cancer, and about changes in life...
6.
Khoshnoud R, He Q, Sylvan M, Khoshnoud A, Ivarsson M, Fornander T, et al.
Int J Mol Med
. 2010 Apr;
25(5):735-41.
PMID: 20372817
cDNA microarray is an established technique. However, difficulties such as handling tissue samples under RNase-free conditions, the heterogeneous tumor composition, i.e. non-malignant versus malignant cells and different pathologic types of...
7.
Randen M, Rutqvist L, Johansson H
Acta Oncol
. 2009 Apr;
48(6):915-20.
PMID: 19363713
Background: Metastatic cancer from an unknown primary tumour (CUP) is a common and heterogeneous clinical entity. In Sweden like in many other countries, the continuum of care for such patients...
8.
Johnsson A, Fornander T, Rutqvist L, Vaez M, Alexanderson K, Olsson M
Acta Oncol
. 2008 Oct;
48(1):93-8.
PMID: 18937082
Background: The most common female cancer in Western countries is breast cancer and women diagnosed with this disease are often under 65 years old. With increasing prevalence of survivors it...
9.
Arriagada R, Rutqvist L, Johansson H, Kramar A, Rotstein S
Acta Oncol
. 2008 Jul;
47(6):1113-21.
PMID: 18607866
Background: Prediction of distant metastases is of paramount importance in the knowledge and management of breast cancer patients. The objective of this study was to assess conventional prognostic factors in...
10.
Khoshnoud M, Fornander T, Johansson H, Rutqvist L
Breast Cancer Res Treat
. 2007 Nov;
107(1):71-8.
PMID: 18043896
Purpose: Recent studies on the pattern of gene expression in estrogen receptor positive and negative tumours have revealed profound differences according to receptor status. However, it remains unclear if these...